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Abstract
Background: The aim of this study was to assess the association of lung function with serum fatty-acid binding
protein 4 (FABP4) in apparently healthy Korean adults.
Methods: In 495 participants in a health screening program, Force Exploratory Volume (FEV) 1 and Forced Vital
Capacity (FVC) were assessed with standard spirometry. Subjects with obstructive (n = 19) and restrictive (n = 45)
lung function were excluded from the analysis. Serum FABP4 level was measured by enzyme-linked immunosorbent
assay and transformed into Ln(FABP4). 431 subjects with normal ventilator function (72.4 % men, mean age 41 years)
were included in the final analysis.
Results: Mean Ln(FABP4) significantly decreased in subjects from 1st quartile to 4th quartile of FVC (p = 0.008).
Ln(FABP4) did not show significant differences across the quartile groups of FEV1. The odds ratio (OR) of being in
the lowest quartile of FVC was 2.704 in subject with 3rd tertile of Ln(FABP4) after full adjustment for confounding
variables {95 % confidence interval (CI) 1.397 ~ 5.357}. OR of being in the lowest quartile of FEV1 was 1.822 (95 % CI
1.021 ~ 3.298) in subjects with 3rd tertile of Ln(FABP4) after adjustment of age and sex, which was attenuated after
full adjustment for confounding variables.
Conclusion: Increased FABP4 level showed increased risk for reduced lung function in subjects with normal
ventilatory function.
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Background
Adipokines, such as leptin, adiponectin, ghrelin, resistin,
and visfatin, are peptides that are secreted from visceral
adipose tissues [1]. Adipocytokines secreted from adipose
tissue are the results of close interactions between adipo-
cytes and immune cells that are infiltrated in adipose tis-
sue. Adipocytokines mediate the crosstalk between
adipose tissues and other metabolic organs in our body,
especially the liver, muscle, pancreas, and the organs of
the central nervous system. They maintain metabolic
homeostasis and their dysfunctions have been causally
linked to a wide range of metabolic diseases [2–4].
Adipocytokines are known to play a role in the
process of development of lung diseases from previous
studies [5]. Ghrelin level in circulation is decreased in
patients with chronic obstructive pulmonary disease
[6]. Visfatin—initially known as pre-B cell colony-
enhancing factor—also plays a critical role in some in-
flammatory processes, the apoptosis of neutrophils, and
the secretion of interleukin-8 from the endothelial cells
of the pulmonary artery in humans [7]. Furthermore,
decreased forced vital capacity (FVC) or forced expira-
tory volume in one second (FEV1), indicating impaired
lung function, is associated with persistent low grade
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systemic inflammation assessed by serum inflammatory
markers, such as C-reactive protein (CRP) [8, 9].
Although emerging evidence has shown that pulmon-
ary dysfunction has a connection with not only cigarette
smoking, but also with obesity, type 2 diabetes, and insu-
lin resistance [9–12], only few studies have investigated
the relationship between reduced lung function and adi-
pocytokine levels. Fatty acid–binding protein 4 (FABP4)
is an adipocytokine that is expressed in both adipocytes
and macrophages [13]. It is known that the FABP4 level
is associated with obesity, insulin resistance, and athero-
sclerosis. It has been reported that FABP4 acts as a posi-
tive regulator of cellular proliferation; therefore its role
in lung function may be important [14]. However, little
is known about the relationship between reduced lung
function and FABP4 levels.
We therefore assessed the association between in-
creased serum FABP4 levels with reduced lung function




This study was performed as a sub-study in the Kangbuk
Samsung Medical Center (KBSMC)-adipokine study,
which is a longitudinal study performed in subjects who
received annual health check-ups at the Health Promotion
Center at Kangbuk Samsung Hospital in Seoul, Korea,
between 2003 and 2007. In 1635 serum samples of the
subjects who participated in annual health check-up in
2003, 499 subjects in whom serum adipocytokine levels
were available, were selected to participate in this study.
Of them, 4 individuals were excluded because they had no
available FEV1 or FVC level measurements. In total of
495 subjects, 45 subjects (9.1 %) had restrictive ventilatory
pattern and 19 subjects (3.8 %) had obstructive pattern.
The final analyses were performed in 431 subjects with
normal ventilatory function after exclusion of these 64
subjects.
The study protocol conformed to ethical guidelines of
the 2000 Declaration of Helsinki, and accordingly the
Kangbuk Samsung Hospital Human Research Committee
approved it. The Kangbuk Samsung Hospital Institutional
Review Board also approved this study. The informed
consent requirement for this study was exempted by the
Institutional Review Board at the time the study was in
the planning phase because researchers only accessed the
database for analysis purposes, which was free of identify-
ing personal information.
Measurement of lung function
Spirometry was performed as recommended by the
American Thoracic Society, using Vmax22 (SensorMedics,
Yorba Linda, CA, USA). Absolute Values of FVC and
FEV1 were obtained and the percentage of predicted
values (% pred) for FEV1 and FVC were calculated from
the following equations obtained in a representative
Korean Population [15].
Predicted FVC ¼ 4:8434 – 0:00008633  age2 years½  
þ 0:05292  height cm½ ð Þ
þ 0:01095  weight kg½ ð Þ
Predicted FEV1 ¼ 3:4132 – 0:0002484  age2 years½  
þ 0:04578  height cm½ ð Þ
The highest FVC and FEV1 values of the tests with ac-
ceptable curves were used. Ventilatory patterns were de-
fined as normal (FVC ≥80 % and FEV1/FVC ≥0.7),
restrictive (FVC <80 % and FEV1/FVC ≥0.7; n = 45;
9.1 %), or obstructive (FEV1/FVC <0.7; n = 19; 3.8 %).
Subjects with normal patterns were subdivided into
quartiles according to the baseline percentage of predicted
values (% predicted) for FVC or FEV1. Based on the FVC,
the resulting four categories were as follows: ≤99.3 % in
quartile 1, 99.3–104.4 % in quartile 2, 104.4–112.7 % in
quartile 3, and >112.7 % in quartile 4. Similarly, the sub-
jects were also divided into quartiles based on the FEV1
values (% predicted): ≤97.9 % in quartile 1, 97.9–106.9 %
in quartile 2, 106.9–118.2 % in quartile 3, and >118.2 % in
quartile 4.
Anthropometric measurements and laboratory tests
Trained physicians carried out the anthropometric mea-
surements including height, weight, and body fat per-
centage. Systolic (SBP) and diastolic blood pressures
(DBP) were measured according to the Hypertension De-
tection and Follow-up Program protocol by using a mer-
cury blood pressure device after the subjects had rested
longer than 5 min [16]. For the cases with a SBP higher
than 140 mmHg and a DBP higher than 90 mmHg, the
BP was measured two more times after resting and the
average value was used. Body mass index (BMI) (kg/m2)
was calculated by dividing the weight (kg) by the squared
height (m).
After 12 h of fasting, blood glucose (FBG), total choles-
terol (TC), triglyceride (TG), high-density lipoprotein
cholesterol (HDL-C), and low-density lipoprotein-
cholesterol (LDL-C) levels were obtained. The hexokinase
method (Advia1650 Autoanalyzer; Bayer Diagnostics, Le-
verkusen, Germany) was used to measure blood glucose
levels and an enzymatic colorimetric test was used to
measure TC and TG levels. The selective inhibition
method was used to measure HDL-C and a homogeneous
enzymatic colorimetric test was used to measure LDL-C.
The fasting serum insulin level was measured by immu-
noradiometric assay (RIABEAD II, Abbott, Tokyo, Japan),
with an intra-assay coefficient of variance of 1.2 to 1.9 %
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and an inter-assay coefficient of variance of 1.4 to 3.3 %.
The results were presented as milligrams per liter and the
limit of measurement was 0.175 mg/L, with a sample dilu-
tion of 1:20. Insulin resistance status was calculated by
using the homeostatic model assessment-insulin resist-
ance (HOMA-IR) [17]. The formula used for calculation
was as follows:
HOMA‐IR ¼ ðfasting insulin ½μIU=mL
 fasting blood glucose mM=LÞ=22:5:
Measurement of serum FABP4 levels
Serum FABP4 levels were measured using an enzyme-
linked immunosorbent assay (ELISA; BioVendor
Laboratory Medicine, Modrice, The Czech Republic).
The intra- and inter-assay coefficients of variation
(CVs) were 5.0 and 9.8 %, respectively.
Subjects were divided into three groups according to
the Ln(FABP4); 1st tertile: Ln(FABP4) < 2.04, 2nd tertile:
2.04 ≤ Ln(FABP4) < 2.41, 3rd tertile: Ln(FABP4) ≥ 2.41.
Evaluation of body composition
Body composition measurements of the subjects were car-
ried out by segmental bioelectric impedance, using eight
tractile electrodes according to the manufacturer’s instruc-
tions (InBody 3•0, Biospace, Korea). Lean mass (kg), fat
mass (kg), percent fat mass (%), and waist-hip ratio
(WHR) as a marker of abdominal obesity, were measured.
Statistical analysis
Statistical analysis was performed with SPSS version 18.0
(PASW Statistics version 18.0 (SPSS Inc., Chicago, IL,
USA). Data are represented as mean descriptive statistics
and were used to describe the mean ± SD. Descriptive sta-
tistics were used to describe the study population at the
baseline. The assessment for the normality of the variables
was done with Kormogorov–Smirnov test and the FABP4
values were log-transformed as they did not follow a nor-
mal distribution. The comparisons of mean values of the
variables among the subdivided groups were performed by
Kruskal-Wallis test or one-way ANOVA and multiple
comparison tests were performed with post hoc analysis.
The chi-square test was used for cross-tabulation analysis.
Stepwise multiple logistic regression analyses were per-
formed to evaluate the associations between FABP4 and
being in the lowest FVC and FEV1 (% pred) quartiles after
adjustment for confounding factors. A 95 % confidence
interval (CI) was determined for each risk. For all statis-
tical tests used, a p value <0.05 was considered significant.
Results
Clinical characteristics of total study participants
according to the ventilatory pattern
Clinical characteristics of the total study population based
on the ventilatory patterns are presented in Table 1. 431
(87.1 %) subjects had normal ventilator pattern, 45 (9.1 %)
had restrictive ventilatory pattern and 19 (3.8 %) subjects
had obstructive ventilatory pattern. Mean age of the partici-
pants was 41 years. Subjects with restrictive ventilator pat-
tern were younger and leaner than subjects with normal
ventilatory pattern. The subjects with obstructive ventila-
tory pattern showed similar metabolic profiles to subjects
with normal ventilatory pattern. There were no significant
differences in FABP4 levels among the three groups.
Further analyses were performed only in subjects with
normal ventilatory function (N = 431).
Comparisons of metabolic components by quartiles of
FVC and FEV1 (% pred) in subjects with normal
ventilatory function
Mean age of the subjects with normal ventilatory function
was 41 years and 312 subjects (72.4 %) were men. When
the mean values of metabolic parameters were compared
according to the quartiles of FVC (% pred), age, HDL-C
and percent body fat showed significant differences among
the groups (Table 2). The mean values of HDL-C and per-
cent body fat decreased from quartile 1 to quartile 4.
Mean Ln(FABP4) significantly decreased from quartile 1
to quartile 4 of FVC (% pred) (Table 2, Fig. 1).
When the mean values of metabolic parameters were
compared according to the quartiles of FEV1 (% pred),
mean values of BMI, BP, HDL-C, percent body fat and
WHR showed significant differences among the groups
(Table 3). The mean values of BMI and BP increased as
the quartiles of FEV1 (% pred) increased from quartile 1
to quartile 4. Mean HDL-C values decreased from quartile
1 to quartile 4. Other components of metabolic syndrome
showed inconsistent results. The mean percent body fat of
1st quartile was significantly lower than other quartile
groups (p < 0.001). The mean Ln(FABP4) values did not
show significant differences across the quartile groups.
When the mean values of the metabolic parameters
were compared between the lowest quartile and other
quartile groups divided by FVC (% pred), mean value of
SBP were significantly lower, and mean values of HDL-C
and percent body fat were significantly higher in the low-
est quartile compared to other quartile groups (Additional
file 1: Table S1). Mean Ln(FABP4) was significantly higher
in the lowest quartile group compared with other quartile
groups. Similar results were observed when the compari-
sons were performed in groups divided by FEV1 (% pred),
except that mean Ln(FABP4) showed only a higher ten-
dency in the lowest quartile compared with other quartile
groups (p = 0.0710) (Additional file 1: Table S2).
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Table 1 Baseline characteristics of total population
All (N = 495) Normal (N = 431) Restrictive (N = 45) Obstructive (N = 19) P value
Age (yrs) 40.83 ± 6.27 41.10 ± 6.30a 38.96 ± 5.95b 39.05 ± 5.46a,b 0.041
Sex: male (%) 327 (66.1) 312 (72.4) 7 (15.6) 8 (42.1) <0.001
BMI (kg/m2) 23.63 ± 2.96 23.90 ± 2.92a 21.50 ± 2.63b 22.59 ± 2.42a,b <0.001
SBP (mmHg) 112.91 ± 12.21 113.48 ± 12.03a 106.67 ± 11.68b 114.74 ± 13.89a,c 0.001
DBP (mmHg) 72.67 ± 9.51 73.11 ± 9.40a 68.00 ± 9.19b 73.68 ± 10.12a,c 0.002
Fasting glucose (mg/dL) 94.40 ± 12.08 94.88 ± 12.40 90.84 ± 10.34 92.05 ± 5.50 0.071
Total cholesterol (mg/dL) 200.89 ± 35.72 203.34 ± 36.05a 182.53 ± 27.36b 188.74 ± 31.66a,b <0.001
Triglyceride (mg/dL) 132.75 ± 111.83 139.19 ± 117.52a 87.13 ± 40.43b 94.74 ± 40.30a,b 0.004
HDL-C (mg/dL) 54.21 ± 11.23 53.88 ± 11.31 57.07 ± 10.18 54.95 ± 11.27 0.185
LDL-C (mg/dL) 114.44 ± 28.11 115.91 ± 28.08a 102.54 ± 26.34b 105.84 ± 26.25a,b 0.008
Fasting insulin (uIU/mL) 6.72 ± 3.45 6.80 ± 3.56a 6.74 ± 2.64a,b 4.83 ± 1.89c 0.051
Percent body fat (%) 23.55 ± 5.47 23.26 ± 5.46a 26.04 ± 4.80b 24.27 ± 5.94a,b 0.004
WHR 0.86 ± 0.05 0.86 ± 0.05a 0.83 ± 0.04b 0.85 ± 0.04a,b <0.001
HOMA-IR 1.58 ± 0.94 1.60 ± 0.96 1.55 ± 0.81 1.11 ± 0.46 0.076
FVC (% pred) 1.01 ± 0.16 1.04 ± 0.13a 0.71 ± 0.08b 1.02 ± 0.16b,c <0.001
FEV1 (% pred) 1.05 ± 0.19 1.09 ± 0.16a 0.75 ± 0.10b 0.76 ± 0.12b <0.001
Ln(FABP4) 2.21 ± 0.45 2.22 ± 0.45 2.18 ± 0.38 2.10 ± 0.52 0.490
Smoking (%) 80 (16.2) 78 (18.1) 1 (2.2) 1 (5.3) 0.009
Different superscripts denote a significant difference between groups
Values were expressed as Mean ± SD or N (%)
BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol,
WHR waist-hip ratio, HOMA-IR homeostasis model assessment-insulin resistance, FVC force vital capacity, FEV1 forced expiratory volume in 1 s, Ln(FABP4) logarithmized
form of fatty-acid binding protein 4
Table 2 Comparisons of metabolic components by quartile of FVC (% pred) among subjects with normal ventilator function
N = 431 1st Quartile 2nd Quartile 3rd Quartile 4th Quartile P value
(≤0.993) (>0.993, ≤ 1.044) (>1.044, ≤ 1.127) (>1.127)
Age (yrs) 42.06 ± 6.4a 42.42 ± 7.2a 39.32 ± 5.0b 40.61 ± 6.0a,b 0.001
Sex: male (%) 58 (53.7)a 84 (77.8)b 79 (73.2)b 91 (84.3)b <0.001
BMI (kg/m2) 23.62 ± 3.3 24.15 ± 3.1 23.84 ± 2.7 23.98 ± 2.5 0.595
SBP (mmHg) 110.83 ± 13.3 113.7 ± 12.0 114.81 ± 11.3 114.58 ± 11.0 0.057
DBP (mmHg) 71.67 ± 10.3 73.43 ± 9.1 73.8 ± 9.7 73.55 ± 8.4 0.325
Fasting glucose (mg/dL) 94.06 ± 11.9 95.84 ± 15.0 94.46 ± 8.8 95.15 ± 13.2 0.733
Total cholesterol (mg/dL) 206.54 ± 40.6 204.56 ± 31.2 202.79 ± 36.2 199.43 ± 35.7 0.522
TG (mg/dL) 140.83 ± 166.7 145.21 ± 121.4 140.4 ± 94.6 130.21 ± 62.7 0.817
HDL-C (mg/dL) 56.41 ± 13.4a 53.48 ± 9.7a,b 52.35 ± 11.5b 53.27 ± 10.0a,b 0.049
LDL-C (mg/dL) 117.16 ± 30.8 116.2 ± 25.1 117.33 ± 27.6 112.86 ± 29.0 0.650
Fasting insulin (uIU/mL) 7.21 ± 4.3 6.61 ± 3.1 6.79 ± 3.6 6.61 ± 3.1 0.571
Percent body fat (%) 24.90 ± 5.8a 23.16 ± 5.8a,b 22.93 ± 4.7b 22.02 ± 5.2b 0.001
WHR 0.86 ± 0.1 0.87 ± 0.1 0.86 ± 0.04 0.87 ± 0.04 0.448
HOMA-IR 1.72 ± 1.3 1.55 ± 0.8 1.6 ± 0.9 1.55 ± 0.8 0.537
Ln(FABP4) 2.34 ± 0.5a 2.21 ± 0.5a,b 2.19 ± 0.4a,b 2.13 ± 0.5b 0.008
Smoking (%) 12 (11.2) 20 (18.7) 20 (18.7) 26 (24.3) 0.095
Different superscripts denote a significant difference between groups
Values were expressed as Mean ± SD or N (%)
FVC forced vital capacity, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, TG triglyceride, HDL-C high-density lipoprotein cholesterol,
LDL-C low-density lipoprotein cholesterol, WHR waist-hip ratio, HOMA-IR homeostasis model assessment-insulin resistance, Ln(FABP4) logarithmized form of fatty-acid
binding protein 4
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Multiple logistic regression analyses for Ln(FABP4) with
lowest quartiles of FVC and FEV1 (% pred) as the
dependent variable in subjects with normal ventilatory
function
Stepwise multiple logistic regression analyses were per-
formed with being in the lowest quartile of FVC (%
pred) as the dependent variable (Table 4). The odds ratio
(OR) of being in the lowest quartile of FVC (% pred)
was 2.193 in subjects with 3rd tertile of Ln(FABP4) after
adjustment for age and sex with the 1st tertile of
Ln(FABP4) as the reference {95 % CI 1.239 ~ 3.949}.
When the analysis was performed with full adjustment
Fig. 1 Comparisons of mean Ln(FABP4) among the quartile groups of FVC (% pred) in subjects with normal lung function
Table 3 Comparisons of metabolic components by quartile of FEV1 (% pred) among subjects with normal ventilator function









Age (yrs) 41.44 ± 6.2 40.02 ± 5.5 41.09 ± 6.6 41.88 ± 6.9 0.163
Sex: male (%) 50 (46.3)a 77 (71.3)b 86 (79.6)b,c 99 (91.7)c <0.001
BMI (kg/m2) 23.66 ± 3.4a,b 23.51 ± 2.7a 23.81 ± 2.8a,b 24.64 ± 2.6b 0.021
SBP (mmHg) 109.54 ± 12.3a 113.52 ± 12.9a,b 114.63 ± 11.4b 116.26b ± 10.5b <0.001
DBP (mmHg) 70.83 ± 10.1a 72.59 ± 9.5a,b 73.98 ± 9.2a,b 75.05 ± 8.4b 0.007
Fasting glucose (mg/dL) 93.69 ± 10.6 93.74 ± 8.9 97.05 ± 15.0 95.05 ± 13.9 0.156
Total cholesterol (mg/dL) 207.75 ± 37.0 198.38 ± 35.0 203.19 ± 35.1 204.04 ± 36.9 0.296
TG (mg/dL) 123.58 ± 159.9 135.86 ± 92.8 142.41 ± 91.9 155.04 ± 111.8 0.260
HDL-C (mg/dL) 57.07a ± 11.6 53.03b ± 12.5 53.29ab ± 11.1 52.11b ± 9.2 0.007
LDL-C (mg/dL) 119 ± 27.5 112.38 ± 27.9 116.16 ± 27.5 116.26 ± 29.5 0.411
Fasting insulin (uIU/mL) 6.87 ± 4.1 6.2 ± 2.8 6.88 ± 3.5 7.28 ± 3.7 0.169
Percent body fat (%) 25.73 ± 5.4a 22.90 ± 5.4b 22.55 ± 5.6b 21.84 ± 4.5b <0.001
WHR 0.86 ± 0.1a,b 0.86 ± 0.04a 0.86 ± 0.04a,b 0.88 ± 0.04b 0.020
HOMA-IR 1.62 ± 1.2 1.45 ± 0.7 1.65 ± 1.0 1.7 ± 0.9 0.248
Ln(FABP4) 2.29 ± 0.5 2.2 ± 0.4 2.19 ± 0.5 2.19 ± 0.4 0.351
Smoking (%) 13 (12.1) 21 (19.6) 20 (18.7) 24 (22.4) 0.254
Different superscripts denote a significant difference between groups
Values were expressed as Mean ± SD or N (%)
FEV1 forced expiratory volume in 1 s, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, HDL-C high-density lipoprotein cholesterol,
LDL-C low-density lipoprotein cholesterol, WHR waist-hip ratio, HOMA-IR homeostasis model assessment-insulin resistance, Ln(FABP4) logarithmized form of fatty-
acid binding protein 4
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for confounding variables, OR for being in the lowest
quartile of FVC (% pred) was 2.704 in subjects with 3rd
tertile of Ln(FABP4) (95 % CI 1.397 ~ 5.357).
Similar analyses were performed with being in the
lowest quartile of FEV1(% pred) as the dependent vari-
able (Table 5). OR of being in the lowest quartile of
FEV1 (% pred) was 1.822 in subjects with 3rd tertile of
Ln(FABP4) after adjustment for age and sex. However,
further adjustment for confounding variables attenuated
the significance (Table 5).
Discussion
Our study is the first study that revealed the association
between FABP4 and lung function. The major finding of
this study was that the concentration of serum FAPB4
increased as the lung function decreased within the nor-
mal range of lung function, after adjustment for a wide
range of variables, including age, gender, current smok-
ing, BP, FBG, BMI, HOMA-IR, lipid profile, and percent
body fat, when the study population was divided into
quartiles based on FVC or FEV1 (% pred). Multiple lo-
gistic regression and stepwise logistic regression revealed
that increased serum FABP4 correlated with an in-
creased risk for reduced lung function, especially show-
ing significant correlation with FVC.
Impaired lung function is known to be associated with an
increased prevalence and mortality of cardiovascular dis-
ease. It is well recognized that severe obesity is associated
with impaired lung function [18, 19]. Most population stud-
ies that examined the relationship between obesity and lung
function used BMI as a measurement of overall adiposity
and insignificant or weak associations have been reported,
with diminished lung function at both extremes of the BMI
distribution [20]. Recently, it was suggested that fat mass,
and fat-free mass might have distinct effects on pulmonary
function. Several studies reported inverse associations be-
tween lung function and measures of central adiposity, such
as the waist circumference and the WHR [21–23]. Al-
though recent studies suggest the association of impaired
lung function and metabolic syndrome with total body fat
[24], there have been few studies investigating the relation-
ship between lung function and the related markers.
Adipocytokines are a group of hormone-like mediators
secreted by adipose tissues. They were first described as
regulators of energy metabolism, but were later also rec-
ognized as being produced by inflammatory cells and be-
ing involved in many immune and inflammatory
processes in the human body [1]. Recently, adipocytokines
have also been found to mediate inflammatory responses
in the human lung, and associations between the levels of
some adipocytokines and obstructive airway diseases have
been described [4–6]. It is not well-known that obesity
may play a significant role in the pathogenesis of pulmon-
ary diseases through mechanisms in association with pro-
inflammatory mediators produced from adipose tissues,
and they contribute to a low-grade systemic inflammation.
Table 4 Multiple logistic regression analyses with lowest
quartile of FVC(% pred) as dependent variable among subjects
with normal ventilator function
OR 95 % CI
Model 1
Ln(FABP4), 1st tertile 1 –
Ln(FABP4), 2nd tertile 1.736 0.969 ~ 3.154
Ln(FABP4), 3rd tertile 2.193 1.239 ~ 3.949
Model 2
Ln(FABP4), 1st tertile 1 –
Ln(FABP4), 2nd tertile 1.817 1.002 ~ 3.340
Ln(FABP4), 3rd tertile 2.337 1.251 ~ 4.451
Model 3
Ln(FABP4), 1st tertile 1 –
Ln(FABP4), 2nd tertile 2.034 1.093 ~ 3.845
Ln(FABP4), 3rd tertile 2.704 1.397 ~ 5.357
Model 1, adjusted for covariates with age, sex; Model 2, adjusted as Model 1
plus significant covariables (smoking, SBP, HDL-C, percent body fat); Model 3,
fully adjusted as Model 2 plus insignificant covariables (fasting glucose, DBP,
TG, LDL-C, fasting insulin, WHR, HOMA-IR, BMI)
FVC forced vital capacity, OR odds ratio, CI confidence interval, Ln(FABP4)
logarithmized form of fatty-acid binding protein 4, SBP systolic blood pressure,
HDL-C high-density lipoprotein cholesterol, DBP diastolic blood pressure, TG
triglyceride, LDL-C low-density lipoprotein cholesterol, WHR waist-hip ratio,
HOMA-IR homeostasis model assessment-insulin resistance; BMI, body
mass index
Table 5 Multiple logistic regression analyses with lowest
quartile of FEV1(% pred) as dependent variable among subjects
with normal ventilatory function
OR 95 % CI
Model 1
Ln(FABP4), 1st tertile 1 –
Ln(FABP4), 2nd tertile 1.547 0.858 ~ 2.819
Ln(FABP4), 3rd tertile 1.822 1.021 ~ 3.298
Model 2
Ln(FABP4), 1st tertile 1 –
Ln(FABP4), 2nd tertile 1.406 0.767 ~ 2.597
Ln(FABP4), 3rd tertile 1.579 0.840 ~ 3.002
Model 3
Ln(FABP4), 1st tertile 1 –
Ln(FABP4), 2nd tertile 1.512 0.816 ~ 2.827
Ln(FABP4), 3rd tertile 1.574 0.819 ~ 3.056
Model 1, adjusted for covariates with age, sex; Model 2, adjusted as Model 1
plus significant covariables (SBP, DBP, HDL-C, body fat percentage); Model 3,
fully adjusted as Model 2 plus insignificant covariables (smoking, glucose, TG,
fasting insulin, percentage body fat, WHR, HOMA-IR, BMI)
FEV1 forced expiratory volume in 1 s, OR odds ratio, CI confidence interval,
Ln(FABP4) logarithmized form of fatty-acid binding protein 4, SBP systolic
blood pressure, DBP diastolic blood pressure, HDL-C high-density lipoprotein
cholesterol, TG triglyceride, WHR waist-hip ratio, HOMA-IR homeostasis model
assessment–insulin resistance, BMI body mass index
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In animal models, inflammatory responses in the lung
have been shown to influence the production of adipocy-
tokines, leptin and adiponectin, cytokines, acute phase
proteins, and other mediators produced by adipose tis-
sues, which may participate in immune responses in lungs
[5, 25, 26]. An increased adipose tissue mass may also in-
fluence susceptibility to pulmonary infections, enhance
pulmonary inflammation associated with environmental
exposures, and exacerbate airway obstruction in preexist-
ing lung diseases [27].
In our study, the FABP level increased as the FVC (%
pred) decreased within the normal range of lung function
after adjustment for other variables. FABP4 belongs to a
family of cytosolic chaperones that are involved in systemic
regulation of lipid and glucose metabolism [13]. FABP4 has
been implicated in several aspects of the metabolic syn-
drome in mice, including insulin resistance and atheroscler-
osis [28–32]. The level of circulating human FABP4 was
proposed as an independent prognostic marker for the de-
velopment of metabolic syndrome, non-alcoholic fatty liver
and diabetes [33–36]. To date, the mechanism by which
FABP4 promotes insulin resistance, inflammation or pul-
monary dysfunction are not fully understood. Decreased
FVC or FEV1 has been shown to be persistent in low-grade
systemic inflammatory status assessed by increased serum
levels of inflammatory markers, such as CRP [8, 9, 37, 38].
Our results imply that FABP4 might also act as a pro-
inflammatory adipocytokine and affect pulmonary function.
Further research is needed to clarify the role of FABP4 on
pulmonary function or inflammation.
Our study has a few limitations. First, our study is cross-
sectional study; therefore, we cannot know the cause-
effect relationship between FABP4 levels and lung func-
tion. Second, the correlation of serum FABP4 and lung
function is limited to the FVC (% pred). The reason why
FABP4 level did not show significant correlation with
FEV1 could not be clarified. Third, as the analyses were
performed regarding the relationship only between the
FABP4 levels and lung function, the possible effects of
other adipocytokines on FABP4 and lung function could
not be separately analyzed. In addition, it could be inter-
esting to see other FABPs such as FABP5 and FABP1 in
relation to lung function in future studies. Despite these
limitations, our study has strength in that this is the first
study that analyzed the relationship between FABP4 and
lung function in apparently healthy adults.
Conclusions
In summary, the results of this study indicate that increased
FABP4 is related with reduced lung function, especially de-
creased FVC (% pred) even after adjustment for confound-
ing factors in subjects with normal lung function. Further
prospective studies are needed to clarify the effect of FABP4
on lung function.
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